These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22759213)

  • 1. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS; Mirkin S; Jenkins SN
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP
    Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S; Currie H; Mikkola TS; Dragon E
    Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
    Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
    J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in menopausal therapy: the tissue-selective estrogen complex.
    Moore A
    J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
    Mirkin S; Komm BS; Pan K; Chines AA
    Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
    Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
    Umland EM; Karel L; Santoro N
    Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
    Pinkerton JV; Komm BS; Mirkin S
    Climacteric; 2013 Dec; 16(6):618-28. PubMed ID: 23805785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective estrogen modulators in menopause.
    Gambacciani M
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.
    Mirkin S; Ryan KA; Chandran AB; Komm BS
    Maturitas; 2014 Jan; 77(1):24-31. PubMed ID: 24246155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
    Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G
    Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL; Santen RJ; Komm B; Mirkin S
    Breast Cancer Res; 2014 Jun; 16(3):212. PubMed ID: 25928299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
    Sharifi M; Lewiecki EM
    Expert Rev Clin Pharmacol; 2014 May; 7(3):281-91. PubMed ID: 24580081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.